Yakup Ergün, Medical Oncologist at Antalya City Hospital, shared a post on X:
“ESMO Breast 2025 is in 5 Days!
One of the key upcoming presentations:
EMBER-3 Subgroup Analysis
- Imlunestrant + abema improved PFS after CDK4/6i (vs. Imlu)
- No abema benefit after abema
- Efficacy observed after palbo and ribo
- Consistent benefit in ESR1+ and PI3K-mutant patients.”
Paolo Tarantino, Research Fellow at Dana-Farber Cancer Institute, shared this post, adding:
“Careful about drawing conclusions on abema after abema based on 23 patients. The HR confidence intervals are incredibly wide (0.37 – 2.31).”
More posts featuring Yakup Ergün and Paolo Tarantino.
